Research output

Research output per year 1996 2013 2014 2016 2017 2018 2019 2020 2021 2022 2023

• 676 Article
• 99 Review article
• 64 Letter
• 33 Comment/debate
• 36 More
  • 18 Chapter
  • 12 Editorial
  • 4 Short survey
  • 1 Book
  • 1 Foreword/postscript

Research output per year

Research output per year

Search results

• 2023

  Prevention of infections including vaccination strategies in multiple myeloma

  Ludwig, H. & Kumar, S., Mar 2023, In: American journal of hematology. 98, S2, p. S46-S62

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Vaccination 80%
  • Infections 48%
  • Chemoprevention 37%
  • Bacterial Infections 31%
• 2022

  Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update

  Lakshman, A. & Kumar, S. K., Jan 1 2022, In: American journal of hematology. 97, 1, p. 99-118 20 p.

  Research output: Contribution to journal › Review article › peer-review

  • Bispecific Antibodies 100%
  • Chimeric Antigen Receptors 95%
  • Immunoconjugates 94%
  • Multiple Myeloma 70%
  • B-Cell Maturation Antigen 62%

• Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

  Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., Yee, A., Kaufman, J. L., Cohen, A. D., Garderet, L., Wechalekar, A. F., Terpos, E., Khatry, N., Niesvizky, R., Yi, Q., Joshua, D. E., & 16 othersSaikia, T., Leung, N., Engelhardt, M., Mothy, M., Branagan, A., Chari, A., Reiman, A. J., Lipe, B., Richter, J., Rajkumar, S. V., Miguel, J. S., Anderson, K. C., Stadtmauer, E. A., Prabhala, R. H., McCarthy, P. L. & Munshi, N. C., Feb 2022, In: The Lancet Haematology. 9, 2, p. e143-e161

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Guidelines 65%
  • Infections 48%
  • Infection Control 25%
  • Immunoglobulins 22%

• Current approaches to management of newly diagnosed multiple myeloma

  Goel, U., Usmani, S. & Kumar, S., May 2022, In: American journal of hematology. 97, S1, p. S3-S25

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Stem Cell Transplantation 58%
  • Proteasome Inhibitors 26%
  • Maintenance 23%
  • Transplants 21%

• Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

  Claveau, J. S., Buadi, F. K. & Kumar, S., Jun 2022, In: Oncology and Therapy. 10, 1, p. 105-122 18 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Allogeneic Cells 100%
  • Stem Cell Transplantation 97%
  • Multiple Myeloma 91%
  • Homologous Transplantation 52%
  • Graft vs Host Disease 48%

• Cutaneous manifestations of monoclonal gammopathy

  Claveau, J. S., Wetter, D. A. & Kumar, S., Apr 2022, In: Blood cancer journal. 12, 4, 58.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Paraproteinemias 100%
  • Skin Manifestations 95%
  • Schnitzler Syndrome 72%
  • Scleromyxedema 65%
  • POEMS Syndrome 62%

• Decoding DNA methylation in epigenetics of multiple myeloma

  Yang, T., Liu, X., Kumar, S. K., Jin, F. & Dai, Y., Jan 2022, In: Blood Reviews. 51, 100872.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • DNA Methylation 99%
  • Epigenomics 88%
  • B-Lymphocytes 22%
  • Dioxygenases 20%

• Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

  Wang, W., Sun, Y., Liu, X., Kumar, S. K., Jin, F. & Dai, Y., Apr 27 2022, In: Frontiers in Oncology. 12, 859455.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Drug Resistance 100%
  • Neoplasms 35%
  • Oncogene Proteins 20%
  • Hematologic Neoplasms 18%
  • Therapeutics 17%

• Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

  Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., Lentzsch, S., McCarthy, P. L., Jagannath, S., Yee, A. J., Little, R. F. & Raje, N. S., Jun 2022, In: Blood cancer journal. 12, 6, 98.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Therapeutics 16%
  • Clinical Trials 14%
  • Proteasome Inhibitors 13%
  • Alkylating Agents 13%

• Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology

  Keren, D. F., Bocsi, G., Billman, B. L., Etzell, J., Faix, J. D., Kumar, S., Lipe, B., McCudden, C., Montgomery, R., Murray, D. L., Rai, A. J., Redondo, T. C., Souter, L., Ventura, C. B. & Ansari, M. Q., May 2022, In: Archives of Pathology and Laboratory Medicine. 146, 5, p. 575-590 16 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Clinical Chemistry 100%
  • Paraproteinemias 96%
  • Clinical Pathology 93%
  • Pathologists 75%
  • Guidelines 49%

• Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma

  Baljevic, M., Sborov, D. W., Lim, M. Y., Hillengass, J., Martin, T., Castillo, J. J., Streiff, M. B., Kumar, S. K. & Callander, N. S., Jan 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 1, p. 91-95 5 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Thromboembolism 100%
  • Venous Thromboembolism 95%
  • Multiple Myeloma 87%
  • Lenalidomide 16%
  • Guidelines 16%

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

  Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., Chadburn, A., Chan, J. K. C., Cheuk, W., Chng, W. J., Choi, J. K., Chuang, S. S., Coupland, S. E., Czader, M., Dave, S. S., de Jong, D., & 63 othersDu, M. Q., Elenitoba-Johnson, K. S., Ferry, J., Geyer, J., Gratzinger, D., Guitart, J., Gujral, S., Harris, M., Harrison, C. J., Hartmann, S., Hochhaus, A., Jansen, P. M., Karube, K., Kempf, W., Khoury, J., Kimura, H., Klapper, W., Kovach, A. E., Kumar, S., Lazar, A. J., Lazzi, S., Leoncini, L., Leung, N., Leventaki, V., Li, X. Q., Lim, M. S., Liu, W. P., Louissaint, A., Marcogliese, A., Medeiros, L. J., Michal, M., Miranda, R. N., Mitteldorf, C., Montes-Moreno, S., Morice, W., Nardi, V., Naresh, K. N., Natkunam, Y., Ng, S. B., Oschlies, I., Ott, G., Parrens, M., Pulitzer, M., Rajkumar, S. V., Rawstron, A. C., Rech, K., Rosenwald, A., Said, J., Sarkozy, C., Sayed, S., Saygin, C., Schuh, A., Sewell, W., Siebert, R., Sohani, A. R., Tooze, R., Traverse-Glehen, A., Vega, F., Vergier, B., Wechalekar, A. D., Wood, B., Xerri, L. & Xiao, W., Jul 2022, In: Leukemia. 36, 7, p. 1720-1748 29 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neoplasms 100%
  • Terminology 51%
  • Spleen 40%
  • Lymph Nodes 36%
• 2021

  Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies

  Bisht, K., Walker, B., Kumar, S. K., Spicka, I., Moreau, P., Martin, T., Costa, L. J., Richter, J., Fukao, T., Macé, S. & van de Velde, H., 2021, In: Expert Review of Hematology. 14, 12, p. 1099-1114 16 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Translational Medical Research 100%
  • Multiple Myeloma 87%
  • Chromosome Aberrations 85%
  • Research Design 70%
  • isatuximab 26%

• Current approaches to management of high-risk multiple myeloma

  Goldman-Mazur, S. & Kumar, S. K., Jul 1 2021, In: American journal of hematology. 96, 7, p. 854-871 18 p.

  Research output: Contribution to journal › Review article › peer-review

  • Risk Management 100%
  • Multiple Myeloma 90%
  • Proteasome Inhibitors 27%
  • Stem Cell Transplantation 23%
  • Transplantation 17%

• Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma

  Zanwar, S. & Kumar, S., 2021, In: Leukemia and Lymphoma. 62, 13, p. 3087-3097 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Inborn Genetic Diseases 46%
  • Biomarkers 32%
  • Plasma Cells 25%
  • Cytogenetics 24%

• Extramedullary disease in multiple myeloma

  Bansal, R., Rakshit, S. & Kumar, S., Sep 2021, In: Blood cancer journal. 11, 9, 161.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Cortical Bone 27%
  • Plasma Cells 25%
  • Cytogenetics 24%
  • Palliative Care 24%

• Initial Therapeutic Approaches to Patients with Multiple Myeloma

  Berbari, H. E. & Kumar, S. K., Jul 2021, In: Advances in Therapy. 38, 7, p. 3694-3711 18 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • daratumumab 43%
  • Plasma Cells 25%
  • Cytogenetics 24%
  • Monoclonal Antibodies 18%

• International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

  Costa, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, N. S., Chng, W. J., Hungria, V., Maiolino, A., Stadtmauer, E., Giralt, S., Pasquini, M., Jakubowiak, A. J., & 16 othersMorgan, G. J., Krishnan, A., Jackson, G. H., Mohty, M., Mateos, M. V., Dimopoulos, M. A., Facon, T., Spencer, A., Miguel, J. S., Hari, P., Usmani, S. Z., Manier, S., McCarthy, P., Kumar, S., Gay, F. & Paiva, B., Jan 2021, In: Leukemia. 35, 1, p. 18-30 13 p.

  Research output: Contribution to journal › Review article › peer-review

  • Residual Neoplasm 100%
  • Multiple Myeloma 93%
  • Clinical Trials 26%
  • Consensus 25%
  • Research Personnel 18%
  6 Scopus citations

• Minimal residual disease in Myeloma: Application for clinical care and new drug registration

  Anderson, K. C., Auclair, D., Adam, S. J., Agarwal, A., Anderson, M., Avet-Loiseau, H., Bustoros, M., Chapman, J., Connors, D. E., Dash, A., Bacco, A. D., Du, L., Facon, T., Flores-Montero, J., Gay, F., Ghobrial, I. M., Gormley, N. J., Gupta, I., Higley, H., Hillengass, J., & 30 othersKanapuru, B., Kazandjian, D., Kelloff, G. J., Kirsch, I. R., Kremer, B., Landgren, O., Lightbody, E., Lomas, O. C., Lonial, S., Mateos, M. V., de Oca, R. M., Mukundan, L., Munshi, N. C., Odonnell, E. K., Orfao, A., Paiva, B., Patel, R., Pugh, T. J., Ramasamy, K., Ray, J., Roshal, M., Ross, J. A., Sigman, C. C., Thoren, K. L., Trudel, S., Ulaner, G., Valente, N., Weiss, B. M., Zamagni, E. & Kumar, S. K., Oct 1 2021, In: Clinical Cancer Research. 27, 19, p. 5195-5212 18 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Residual Neoplasm 100%
  • Multiple Myeloma 53%
  • Pharmaceutical Preparations 38%
  • Clinical Trials 26%
  • Smoldering Multiple Myeloma 21%

• Systemic amyloidosis from A (AA) to T (ATTR): a review

  Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., Kumar, S. K. & Gertz, M. A., Mar 2021, In: Journal of Internal Medicine. 289, 3, p. 268-292 25 p.

  Research output: Contribution to journal › Review article › peer-review

  • Amyloidosis 100%
  • Amyloid 51%
  • Protein Precursors 45%
  • Proteostasis Deficiencies 27%
  • Firearms 20%
  1 Scopus citations

• The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance

  Castillo, J. J., Callander, N. S., Baljevic, M., Sborov, D. W. & Kumar, S., Jul 1 2021, In: American journal of hematology. 96, 7, p. 846-853 8 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Paraproteinemias 100%
  • Kidney 42%
  • Monoclonal Gammopathy of Undetermined Significance 33%
  • Waldenstrom Macroglobulinemia 10%
  • B-Cell Chronic Lymphocytic Leukemia 8%

• The mechanisms and therapeutic targets of ferroptosis in cancer

  Ye, L., Jin, F., Kumar, S. K. & Dai, Y., 2021, In: Expert opinion on therapeutic targets. 25, 11, p. 965-986 22 p.

  Research output: Contribution to journal › Review article › peer-review

  • Ferroptosis 100%
  • Inducer 73%
  • Lipid 21%
  • Neoplasms 20%
  • Cell Death 16%

• Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update

  Muchtar, E., Dispenzieri, A., Gertz, M. A., Kumar, S. K., Buadi, F. K., Leung, N., Lacy, M. Q., Dingli, D., Ailawadhi, S., Bergsagel, P. L., Fonseca, R., Hayman, S. R., Kapoor, P., Grogan, M., Abou Ezzeddine, O. F., Rosenthal, J. L., Mauermann, M., Siddiqui, M., Gonsalves, W. I., Kourelis, T. V., & 18 othersLarsen, J. T., Reeder, C. B., Warsame, R., Go, R. S., Murray, D. L., McPhail, E. D., Dasari, S., Jevremovic, D., Kyle, R. A., Lin, Y., Lust, J. A., Russell, S. J., Hwa, Y. L., Fonder, A. L., Hobbs, M. A., Rajkumar, S. V., Roy, V. & Sher, T., Jun 2021, In: Mayo Clinic proceedings. 96, 6, p. 1546-1577 32 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Immunoglobulin Light-chain Amyloidosis 100%
  • Consensus 70%
  • Cell- and Tissue-Based Therapy 17%
  • Psychology Recognition 16%
  • Therapeutics 12%

• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

  Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., Cavo, M., & 50 othersKristinsson, S. Y., Lentzsch, S., Hajek, R., Anderson, K. C., João, C., Einsele, H., Sonneveld, P., Engelhardt, M., Fonseca, R., Vangsted, A., Weisel, K., Baz, R., Hungria, V., Berdeja, J. G., Leal da Costa, F., Maiolino, A., Waage, A., Vesole, D. H., Ocio, E. M., Quach, H., Driessen, C., Bladé, J., Leleu, X., Riva, E., Bergsagel, P. L., Hou, J., Chng, W. J., Mellqvist, U. H., Dytfeld, D., Harousseau, J. L., Goldschmidt, H., Laubach, J., Munshi, N. C., Gay, F., Beksac, M., Costa, L. J., Kaiser, M., Hari, P., Boccadoro, M., Usmani, S. Z., Zweegman, S., Holstein, S., Sezer, O., Harrison, S., Nahi, H., Cook, G., Mateos, M. V., Rajkumar, S. V., Dimopoulos, M. A. & Richardson, P. G., Mar 2021, In: The Lancet Oncology. 22, 3, p. e105-e118

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Income 62%
  • Therapeutics 16%
  • Pharmaceutical Preparations 10%
  2 Scopus citations
• 2020

  Bonanza of new treatment regimens for multiple myeloma: What is right for my patient?

  Kumar, S. K., Dec 2020, In: JNCCN Journal of the National Comprehensive Cancer Network. 18, p. 1773-1776 4 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Patient Rights 100%
  • Multiple Myeloma 91%
  • Therapeutics 15%
  • Chronic Disease 13%
  • Survival 10%

• Immune-based therapies in the management of multiple myeloma

  Zanwar, S., Nandakumar, B. & Kumar, S., Aug 1 2020, In: Blood cancer journal. 10, 8, 84.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Proteasome Inhibitors 30%
  • isatuximab 26%
  • daratumumab 21%
  • Therapeutics 16%
  1 Scopus citations

• Role of imaging in multiple myeloma

  Baffour, F. I., Glazebrook, K. N., Kumar, S. K. & Broski, S. M., Aug 1 2020, In: American journal of hematology. 95, 8, p. 966-977 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Bone Diseases 37%
  • Bone Marrow 24%
  • Tomography 22%
  • Magnetic Resonance Imaging 22%
  2 Scopus citations

• Systemic Amyloidosis Due to Clonal Plasma Cell Diseases

  Bianchi, G. & Kumar, S., Dec 2020, In: Hematology/Oncology Clinics of North America. 34, 6, p. 1009-1026 18 p.

  Research output: Contribution to journal › Review article › peer-review

  • Amyloidosis 100%
  • Plasma Cells 89%
  • Immunoglobulin Light Chains 81%
  • Light 42%
  • Immunoglobulin Light-chain Amyloidosis 40%
• 2019

  Cell cycle regulation and hematologic malignancies

  Dai, Y., Jin, F., Wu, W. & Kumar, S. K., 2019, In: Blood Science. 1, 1, p. 34-43 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Hematologic Neoplasms 100%
  • Cell Cycle 77%
  • Cell Division 26%
  • Epigenomics 24%
  • Cyclin A1 24%

• Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma

  Kumar, S. K., Glazebrook, K. N. & Broski, S., Jan 1 2019, In: PET Clinics.

  Research output: Contribution to journal › Review article › peer-review

  • Fluorodeoxyglucose F18 100%
  • Multiple Myeloma 93%
  • tomography 74%
  • Bone Marrow 69%
  • Tomography 64%
  5 Scopus citations

• International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

  Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M. V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Serra, E. R., Du, J., van de Donk, N., Berdeja, J. G., Terpos, E., Zamagni, E., Kyle, R. A., San Miguel, J., Goldschmidt, H., Giralt, S., Kumar, S., & 15 othersRaje, N., Ludwig, H., Ocio, E., Schots, R., Einsele, H., Schjesvold, F., Chen, W. M., Abildgaard, N., Lipe, B. C., Dytfeld, D., Wirk, B. M., Drake, M., Cavo, M., Lahuerta, J. J. & Lentzsch, S., Jun 2019, In: The Lancet Oncology. 20, 6, p. e302-e312

  Research output: Contribution to journal › Review article › peer-review

  • Plasma Cells 100%
  • Multiple Myeloma 65%
  • Bone Marrow 24%
  • Bone and Bones 19%
  • Bone Diseases 18%
  84 Scopus citations

• Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

  Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., Malek, E., & 11 othersMartin, T., Omel, J., Raje, N., Sborov, D., Singhal, S., Stockerl-Goldstein, K., Tan, C., Weber, D., Johnson-Chilla, A., Keller, J. & Kumar, R., 2019, In: JNCCN Journal of the National Comprehensive Cancer Network. 17, 10, p. 1154-1165 12 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Guidelines 65%
  • Smoldering Multiple Myeloma 54%
  • Paraproteinemias 42%
  • Plasmacytoma 42%
  39 Scopus citations

• Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing

  Kumar, S. K., Buadi, F. K. & Vincent Rajkumar, S., Feb 14 2019, In: Blood. 133, 7, p. 652-659 8 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Autografts 100%
  • Stem Cell Transplantation 96%
  • Multiple Myeloma 90%
  • Drug 48%
  • Time 21%
  19 Scopus citations

• Targeted management strategies in multiple myeloma

  Kumar, S. K., Jan 1 2019, In: Cancer Journal (United States). 25, 1, p. 59-64 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Clonal Evolution 28%
  • Treatment Failure 19%
  • Drug Resistance 18%
  • Therapeutics 16%
  2 Scopus citations

• The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies

  Harding, T., Baughn, L., Kumar, S. & Van Ness, B., Apr 1 2019, In: Leukemia. 33, 4, p. 863-883 21 p.

  Research output: Contribution to journal › Review article › peer-review

  • Precision Medicine 100%
  • Multiple Myeloma 91%
  • Drug Resistance 84%
  • Technology 60%
  • Biomarkers 34%
  19 Scopus citations

• Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline

  Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., Omel, J., Peswani, N., Prica, A., Raje, N., Seth, R., Vesole, D. H., Walker, I., Whitley, A., Wildes, T. M., Wong, S. W., & 1 othersMartin, T., 2019, In: Journal of Clinical Oncology. 37, 14, p. 1228-1263 36 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Practice Guidelines 94%
  • Joints 71%
  • Guidelines 65%
  • Radiation Oncology 61%
  73 Scopus citations

• Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

  Gonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Chanan Khan, A. A., Dingli, D., Dispenzieri, A., Fonseca, R., Hayman, S. R., Kapoor, P., Kourelis, T. V., Lacy, M. Q., Larsen, J. T., Muchtar, E., Reeder, C. B., Sher, T., Stewart, A. K., Warsame, R., Go, R. S., Kyle, R. A., & 14 othersLeung, N., Lin, Y., Lust, J. A., Russell, S. J., Zeldenrust, S. R., Fonder, A. L., Hwa, Y. L., Hobbs, M. A., Mayo, A. A., Hogan, W. J., Rajkumar, S. V., Kumar, S. K., Gertz, M. A. & Roy, V., Mar 1 2019, In: Bone Marrow Transplantation. 54, 3, p. 353-367 15 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Hematopoietic Stem Cell Transplantation 100%
  • Multiple Myeloma 92%
  • Stem Cells 68%
  • Transplants 58%
  • Therapeutics 15%
  38 Scopus citations
• 2018

  Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma

  Chakraborty, R., Hamilton, B. K., Hashmi, S. K., Kumar, S. K. & Majhail, N. S., Aug 2018, In: Biology of Blood and Marrow Transplantation. 24, 8, p. 1546-1553 8 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Stem Cell Transplantation 100%
  • Multiple Myeloma 94%
  • Quality of Life 61%
  • Manuscripts 12%
  • Symptom Flare Up 12%
  13 Scopus citations

• Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

  Richardson, P. G., San Miguel, J. F., Moreau, P., Hajek, R., Dimopoulos, M. A., Laubach, J. P., Palumbo, A., Luptakova, K., Romanus, D., Skacel, T., Kumar, S. K. & Anderson, K. C., Nov 1 2018, In: Blood cancer journal. 8, 11, 109.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Clinical Trials 65%
  • Clinical Studies 23%
  • Controlled Clinical Trials 18%
  • Therapeutics 16%
  72 Scopus citations

• Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond

  Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X. & Anderson, K. C., Feb 1 2018, In: Leukemia. 32, 2, p. 252-262 11 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Immunotherapy 89%
  • daratumumab 68%
  • Antibodies 56%
  • Dexamethasone 55%
  122 Scopus citations

• Minimal residual disease analysis in myeloma–when, why and where

  Yanamandra, U. & Kumar, S. K., Aug 3 2018, In: Leukemia and Lymphoma. 59, 8, p. 1772-1784 13 p.

  Research output: Contribution to journal › Review article › peer-review

  • Residual Neoplasm 100%
  • Multiple Myeloma 34%
  • Genomic Instability 12%
  • Decision Making 9%
  • Clinical Trials 7%
  9 Scopus citations

• Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines

  Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C. A., Kang, Y., Kassim, A., Liedtke, M., Malek, E., Martin, T., & 10 othersNeppalli, V. T., Omel, J., Raje, N., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Weber, D., Yahalom, J., Kumar, R. & Shead, D. A., Jan 1 2018, In: JNCCN Journal of the National Comprehensive Cancer Network. 16, 1, p. 11-20 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Guidelines 65%
  • Aftercare 39%
  • Therapeutics 11%
  75 Scopus citations

• The multiple myelomas - Current concepts in cytogenetic classification and therapy

  Kumar, S. K. & Rajkumar, S. V., Jul 1 2018, In: Nature Reviews Clinical Oncology. 15, 7, p. 409-421 13 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • Cytogenetics 99%
  • Chromosome Aberrations 58%
  • Chromosomes 47%
  • Smoldering Multiple Myeloma 32%
  83 Scopus citations
• 2017

  Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference

  Yanamandra, U., Khattry, N., Kumar, S., Raje, N., Jain, A., Jagannath, S., Menon, H., Kumar, L., Varma, N., Varma, S., Saikia, T., Malhotra, P., for IMAGe Group, IMAG. G., Bhave, A., Sharma, A., Tripathi, A. K., Khadwal, A., Aribandi, A., Ramesh, A., Dixit, A., & 58 othersDevasia, A. J., Batra, C., Subash, C., Choudhary, D., Bhurani, D., Lad, D., Jijina, F., Prakash, G., Jaishetwar, G., Khurana, H., Malhotra, H., Kohli, H. S., Pinto, I., Rasool, J., Sarin, J., Bhattacharyya, J., Singh, C. J., Babu, K. G., Pavithran, K., Subramanian, K., John, M. J., Sachdeva, M. U. S., Bhattacharyya, M., Agarwal, M. B., Sengar, M., Kumar, N., Sood, N., Chakravarti, P., Subramanian, P. G., Sharma, P., Tembhare, P., Mishra, P., Ganesan, P., Naithani, R., Ahmed, R., Gupta, R., Bansal, R., Nada, R. I., Arora, R., Kapoor, R., Das, R., Nair, R., Shah, S., Kumari, S., Damodar, S., Gupta, S., Melinkeri, S., Naseem, S., Sreedharanunni, S., Chakrabarti, S., Gundeti, S., Das, S. R., Nityanand, S., Bhatwadekar, S., Prinja, S., Singh, T., Suri, V. & Nair, V., Mar 1 2017, In: Indian Journal of Hematology and Blood Transfusion. 33, 1, p. 15-21 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • India 88%
  • Internationality 67%
  • Drug Approval 65%
  • Guidelines 65%
  8 Scopus citations

• Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016

  Tandon, N. & Kumar, S. K., Jun 1 2017, In: Indian Journal of Hematology and Blood Transfusion. 33, 2, p. 153-158 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • daratumumab 100%
  • Hematology 94%
  • Multiple Myeloma 87%
  • selinexor 54%
  • bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine 52%

• New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib

  Richardson, P. G., Kumar, S., Laubach, J. P., Paba-Prada, C., Gupta, N., Berg, D., van de Velde, H. & Moreau, P., Aug 22 2017, In: Journal of Blood Medicine. 8, p. 107-121 15 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • ixazomib 100%
  • Multiple Myeloma 56%
  • Lenalidomide 15%
  • Quality of Life 14%
  • Proteasome Inhibitors 13%
  12 Scopus citations

• Role of ¹⁸F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

  Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengass, J., Engelhardt, M., Usmani, S. Z., Vesole, D. H., San-Miguel, J., Kumar, S. K., Richardson, P. G., Mikhael, J. R., da Costa, F. L., Dimopoulos, M. A., Zingaretti, C., Abildgaard, N., Goldschmidt, H., Orlowski, R. Z., & 8 othersChng, W. J., Einsele, H., Lonial, S., Barlogie, B., Anderson, K. C., Rajkumar, S. V., Durie, B. G. M. & Zamagni, E., Apr 1 2017, In: The Lancet Oncology. 18, 4, p. e206-e217

  Research output: Contribution to journal › Review article › peer-review

  • Fluorodeoxyglucose F18 100%
  • Plasma Cells 95%
  • Multiple Myeloma 93%
  • Smoldering Multiple Myeloma 61%
  • Plasmacytoma 47%
  199 Scopus citations

• Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

  Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., Kourelis, T., Kumar, S. K., Kyle, R. A., Lacy, M. Q., Leung, N., Lin, Y., Lust, J. A., Mikhael, J. R., Reeder, C. B., Roy, V., & 7 othersRussell, S. J., Sher, T., Stewart, A. K., Warsame, R., Zeldenrust, S. R., Rajkumar, S. V. & Chanan Khan, A. A., Apr 1 2017, In: Mayo Clinic proceedings. 92, 4, p. 578-598 21 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Guidelines 65%
  • Recurrence 28%
  • Patient Care 26%
  • Decision Trees 20%
  70 Scopus citations

• Treating Multiple Myeloma Patients With Oral Therapies

  Kumar, S. K., Vij, R., Noga, S. J., Berg, D., Brent, L., Dollar, L. & Chari, A., May 2017, In: Clinical Lymphoma, Myeloma and Leukemia. 17, 5, p. 243-251 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Myeloma 100%
  • ixazomib 19%
  • pomalidomide 18%
  • Panobinostat 17%
  • Therapeutics 16%
  19 Scopus citations
• 2016

  Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

  Tandon, N., Ramakrishna, V. & Kumar, S. K., May 6 2016, In: Clinical Pharmacology: Advances and Applications. 8, p. 35-44 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Histone Deacetylase Inhibitors 100%
  • Multiple Myeloma 84%
  • Panobinostat 19%
  • Bortezomib 14%
  • Proteasome Inhibitors 14%
  29 Scopus citations